Adeno-associated virus library
US-2020370039-A1 · Nov 26, 2020 · US
US2024024507A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024024507-A1 |
| Application number | US-202118255154-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 1, 2021 |
| Priority date | Dec 1, 2020 |
| Publication date | Jan 25, 2024 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are compositions including targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising an amino acid sequence of N-x-(T/I/V/A)-(K/R) (SEQ ID NO: 47). Compositions providing such conjugates, targeting peptides, or recombinant vectors having a mutant capsid or envelope protein are provided as are uses thereof.
Opening claim text (preview).
1 . A recombinant adeno-associated virus (AAV) particle (rAAV) having an AAV capsid comprising an amino acid sequence that comprises a motif N-x-(T/I/V/A)-(K/R) (SEQ ID NO: 47), wherein the amino acid sequence is part of at least the AAV vp3 protein in the AAV capsid, and wherein the rAAV comprises a vector genome packaged in the AAV capsid, wherein the vector genome comprises a nucleic acid sequence encoding a gene product under control of sequences which direct expression thereof, provided that the AAV capsid is not a mutant AAV2 capsid comprising an NDVRAVS (SEQ ID NO: 48) sequence. 2 . The rAAV of claim 1 , wherein the amino acid sequence comprising—the N-x-(T/I/V/A)-(K/R) motif is optionally flanked at the amino terminus and/or the carboxy terminus of the motif by two amino acids to seven amino acids, and is inserted into the AAV capsid vp3 region. 3 . The rAAV of claim 1 , wherein the motif sequence inserted into the AAV capsid comprises: (a) (SEQ ID NO: 40) SSNTVKLTSGH; (b) (SEQ ID NO: 38) EFSSNTVKLTS; (c) (SEQ ID NO: 46) GGVLTNIARGEYMRGG; (d) (SEQ ID NO: 43) GGIEINATRAGTNLGG; (e) (SEQ ID NO: 39) GGSSNTVKLTSGHGG; (f) (SEQ ID NO: 42) IEINATRAGTNL; or (g) (SEQ ID NO: 41) SANFIKPTSY. 4 . The rAAV of claim 1 , wherein the amino acid sequence of the motif is NTVK. 5 . The rAAV of claim 1 , wherein the motif N-x-(T/I/V/A)-(K/R) (SEQ ID NO: 47) is optionally flanked by two to seven amino acids at its carboxy- and/or amino terminus and inserted between amino acids 588 and 589 of an AAV9 capsid protein, based on the numbering of amino acid sequence: SEQ ID NO: 44. 6 . A composition comprising a stock of the rAAV of claim 1 and one or more of a physiologically compatible carrier, excipient, and/or aqueous suspension base. 7 . An endothelial cell targeting peptide, wherein the endothelial cell targeting peptide comprises a motif comprising an amino acid sequence of N-x-(T/I/V/A)-(K/R) (SEQ ID NO: 47) optionally flanked at the amino terminus and/or the carboxy terminus of the motif by two amino acids to seven amino acids, and optionally further conjugated to a nanoparticle, a second molecule, or a viral capsid protein. 8 . The endothelial cell targeting peptide of claim 7 , wherein the endothelial cell targeting peptide comprises: (a) (SEQ ID NO: 40) SSNTVKLTSGH; (b) (SEQ ID NO: 38) EFSSNTVKLTS; (c) (SEQ ID NO: 46) GGVLTNIARGEYMRGG; (d) (SEQ ID NO: 43) GGIEINATRAGTNLGG; (e) (SEQ ID NO: 39) GGSSNTVKLTSGHGG; (f) (SEQ ID NO: 42) IEINATRAGTNL; or (g) (SEQ ID NO: 41) SANFIKPTSY. 9 . The endothelial cell targeting peptide of claim 7 , wherein the amino acid sequence of the motif is NTVK. 10 . A composition comprising the endothelial cell targeting peptide of claim 7 and one or more of a physiologically compatible carrier, excipient, and/or aqueous suspension base. 11 . A fusion polypeptide or protein comprising a brain endothelial cell targeting peptide of claim 7 and a fusion partner which comprises at least one polypeptide or protein. 12 . A composition comprising a fusion polypeptide or protein of claim 11 and one or more of a physiologically compati
the non-active part being polymeric · CPC title
Viral vectors · CPC title
viral · CPC title
Coronaviridae, e.g. avian infectious bronchitis virus · CPC title
from mammals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.